by Kenaan HT, Duncan RM, Al-Jamal WT, Jones DS, Andrews GP, Gilmore B, Yardley V, Farrington N, Stott KE, Lawrence D, Jarvis JN, Harrison TS, Robinson S, Ribeiro I, Hope W, Tian Y. International Journal of Pharmaceutics X 2026;11:100478. doi: 10.1016/j.ijpx.2025.100478
Summary: Bacterial, fungal, and protozoan infections pose a rapidly escalating threat to global health, exacerbated by the rise in antimicrobial resistance. Current therapies against microbial pathogens are limited by high systemic toxicity and poor drug solubility. Liposomal formulations (spherical vesicles composed of lipid bilayers) of antimicrobials can reduce the toxicity and enhance efficacy against bacterial and fungal infections through barrier penetration and extended release. Despite therapeutic advances, successful clinical translation and widespread adoption of liposomal antimicrobials remain highly dependent on overcoming existing technological and manufacturing challenges. The authors of this review advocate for simple liposomal formulation design and scalable manufacturing technologies to ensure affordable global access and to accelerate progress in curbing antimicrobial resistance.
The post Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges first appeared on DNDi.